Second-Generation Antipsychotics - Aripiprazole Revisited
Aripiprazole (Abilify - Bristol-Myers Squibb/Otsuka), a second-generation (atypical) antipsychotic drug, was approved by the FDA in 2002 for treatment of schizophrenia and more recently for bipolar disorder as well. It has been promoted as causing fewer adverse effects than other antipsychotics, without sacrificing efficacy....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Second-Generation Antipsychotics - Aripiprazole Revisited
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1219
Article Code: 1219a
Date: October 10, 2005
Volume: 47
Pages: 81-82
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1219
Article Code: 1219a
Date: October 10, 2005
Volume: 47
Pages: 81-82
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)